Placebo first

DRUG6 trials

Sponsors

University of North Carolina, Chapel Hill, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), New York State Psychiatric Institute, Medical College of Wisconsin, Yale University

Conditions

Cardiovascular DiseaseCystic FibrosisDiabetes Mellitus, Type 2Growth Hormone DeficiencyMajor Depressive DisorderObesityOpioid AbuseOpioid Dependence

Early Phase 1

Influence of Medication on Functional Connectivity

CompletedNCT03612713

Yale UniversityPrescription Drug Abuse (Not Dependent)

Start: 2018-10-30End: 2022-06-02Updated: 2024-03-08

Phase 1

Free Fatty Acids, Body Weight, and Growth Hormones Secretion in Children

TerminatedNCT01237041

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)Growth Hormone Deficiency, Obesity, Short Stature

Start: 2011-07-01End: 2017-12-13Updated: 2018-12-17

Phase 2

Effect of Lucinactant on Mucus Clearance in Cystic Fibrosis Lung Disease

CompletedNCT00934362

University of North Carolina, Chapel HillCystic Fibrosis

Start: 2008-10-31End: 2010-08-31Updated: 2017-03-13

Effects of Ibudilast on Oxycodone Self-administration in Opioid Abusers

CompletedNCT01740414

New York State Psychiatric InstituteOpioid Abuse, Opioid Dependence

Start: 2012-11-30End: 2017-05-31Updated: 2017-08-17

Microdosing Psychedelics to Improve Mood

CompletedNCT05259943

Rotem PetrankerMajor Depressive Disorder

Start: 2023-07-15End: 2025-02-01Updated: 2025-12-30

Unknown Phase

Effect of Probiotic Supplementation on Endothelial Function II

CompletedNCT03267758

Medical College of WisconsinCardiovascular Disease, Diabetes Mellitus, Type 2

Start: 2018-05-15End: 2025-10-16Updated: 2026-03-24

Related Papers

Microdosing psilocybin for major depressive disorder: study protocol for a phase II double-blind placebo-controlled randomised partial crossover trial.

2026-02-16